LipiScan system is a near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and known to complicate stenting procedures.

InfraReDx expects to discuss with attending clinical and interventional cardiologists, cardiac and vascular surgeons and other cardiovascular professionals on LipiScan’s abilities in identifying and characterizing lipid core (fatty) plaques and the importance of this technology.

The LipiScan near-infrared (NIR) spectroscopy catheter is the FDA-cleared product to detect and assess the intracoronary composition of lipid core plaque, which cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms. Lipid core-containing plaque (LCP) is believed to be ‘vulnerable plaque’ that can rupture and form dangerous blood clots leading to coronary thrombosis.

Massachusetts-based InfraReDx is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries.